New scan could spot cancer marker better than current tests

NCT ID NCT06369831

Recruiting now Diagnosis Sponsor: Abscint NV/SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of PET/CT scan that uses a radioactive tracer called 68Ga-ABS011 to detect HER2, a protein found on some cancer cells. The goal is to see if this scan can more accurately determine HER2 status in people with metastatic breast cancer or other solid tumors that have spread. Researchers will compare the scan results with standard biopsy and imaging methods. The study involves 60 adults and aims to improve how doctors choose the right treatments for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER METASTATIC SOLID CANCER

Contacts and locations

Locations

AZ Delta CHIREC
RECRUITING

Brussels, Brussels Capital, 1070, Belgium
Cliniques Universitaires Saint-Luc
RECRUITING

Brussels, Brussels Capital, 1070, Belgium
Free University Brussels (VUB)
RECRUITING

Brussels, Brussels Capital, 1070, Belgium
Institut Jules Bordet
RECRUITING

Brussels, Brussels Capital, 1070, Belgium
Medizinische Universität Innsbruck
RECRUITING

Innsbruck, Tyrol, A-6020, Austria
OLV Aalst
COMPLETED

Aalst, East-Flanders, 9300, Belgium
University Hospital Gasthuisberg
RECRUITING

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.